当前位置:首页 >英文主页 >中英对照 > 中译版报告详情

艾昆纬(IQVIA):2026全球医药销售团队和营销渠道绩效年度回顾报告(中译版)(36页).pdf

上传人: 小*** 编号:1272897 2026-06-30 36页 3.24MB

下载:

1、 2026.All rights reserved.IQVIA is a registered trademark of IQVIA Inc.in the United States,the European Union,and various other countries.An annual review of pharmaceutical sales force and marketing channel performanceChannelDynamicsGlobal Reference 2026:June ReportJAN 2025 DEC 2025Global2002About

2、ChannelDynamics004Summary009Global snapshots011Global data024Country data510OneKey515AppendixGlobal overview 2025011Investment by marketing channel012Investment by corporation,brand,therapy area013Sales force rep equivalents(FTE)014Analysis on the top 15 companies015Channel impact and reach016Omni p

3、ersonal vs.omni non-personal investment growth017Sales force effectiveness metrics018Source of digital engagement019Channel preference020Digital profile021Oncology investment by corporation,brand and cancer type022Channel volume trends023Net Promoter ScoreSM AnalysisNote:Net Promoter ScoreSM is serv

4、ice marks of Bain&Company,Inc.,NICE Systems,Inc.,and Fred Reichheld.IQVIA ChannelDynamics Global Reference 2026As part of IQVIAs Global Market Insights,ChannelDynamics offers marketing channel performance metrics across 36 countries.This publication provides an overview of 2025 pharmaceutical indust

5、ry marketing channel trends worldwide and at the country level.2026.All rights reserved.IQVIA is a registered trademark of IQVIA Inc.in the United States,the European Union,and various other countries.3IQVIA ChannelDynamicsAbout this publicationChannelDynamics is a syndicated database of projected p

6、romotional volume measures and channel performance metrics at company,indication and brand level.As standard,updated monthly and containing 7 years of historical data.Over 30,000 HCPs across 36 countries are recruited to ChannelDynamics specialist panels.Participants continuously fulfil an online da

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. 全球医药营销投入达713亿美元,同比增长8.2%,其中个人渠道(如面对面拜访)增长9.3%至514亿美元,非个人渠道增长5.6%至199亿美元。 2. 8家头部企业增加渠道投入,礼来、辉瑞、勃林格殷格翰增长显著,肥胖与代谢疾病领域(如Mounjaro、Wegovy)驱动创新增长。 3. HCP偏好混合互动,39%仍倾向面对面拜访,数字渠道主要提升覆盖频次而非替代。 4. 销售团队效率指标:平均拜访时长4.7分钟,代表发起的邮件转化率(61%)高于集中化活动(39%)。 5. 肿瘤领域投入持续增长,Keytruda、Pluvicto等品牌领跑,非小细胞肺癌、乳腺癌为主要投入癌种。
**药企投入趋势?** **渠道偏好如何?** **数字渠道增长?**
客服
商务合作
小程序
服务号
折叠